36725-34-5

Basic information

• Product Name: 3(2H)-Pyridazinone, 6-(3,4-dichlorophenyl)-4,5-dihydro-
• CAS NO: 36725-34-5
• Molecular Formula: C10H8Cl2N2O
• Molecular Weight: 243.092
• Mol File: 36725-34-5.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 3(2H)-Pyridazinone, 6-(3,4-dichlorophenyl)-4,5-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 3(2H)-Pyridazinone, 6-(3,4-dichlorophenyl)-4,5-dihydro-(36725-34-5)
• EPA Substance Registry System: 3(2H)-Pyridazinone, 6-(3,4-dichlorophenyl)-4,5-dihydro-(36725-34-5)

Safety Data

• Hazardous Substances Data: 36725-34-5(Hazardous Substances Data)

Upstream product

• 2642-63-9 3',4'-dichloroacetophenone 
• 95-50-1 1,2-dichloro-benzene 
• 95652-74-7 methyl 4-(3',4'-dichlorophenyl)-4-oxo-butanoate 
• 50597-19-8 3-(3,4-dichlorobenzoyl)-propionic acid 
• 75381-58-7 ethyl 4-(3,4-dichlorophenyl)-4-oxobutanoate 

Downstream Products

• 159800-51-8 3-(3,4-dichlorophenyl)-1,4,5,6-tetrahydropyridazine 
• 58059-30-6 3-chloro-6-(3,4-dichlorophenyl)pyridazine 
• 66549-46-0 6-(3,4-dichlorophenyl)-1,2,4-triazolo[4,3-b]pyridazine 
• 66549-48-2 6-(3,4-dichloro-phenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine 
• 55901-92-3 6-(3,4-Dichlorophenyl)-3(2H)-pyridazinone 

Relevant articles and documents

Synthesis, anti-convulsant activity and molecular docking study of novel thiazole pyridazinone hybrid analogues

Pyridazinone analogues have been known to be potential candidates for anticonvulsant agents. We have identified several pyridazinone-based anticonvulsant agents. As a continuation to our previous research, a series of hybrid pyridazinone-thiazole connected through amide linkage were designed and synthesized. Among these, compound SP-5F demonstrated significant anticonvulsant activity with median effective dose of 24.38 mg/kg (MES) and 88.23 mg/kg (scPTz). Results of GABA estimation showed a marked increase in the GABA level when compared with control. Molecular docking studies at the active site of GABA receptor, further confirmed the GABA modulatory effects of SP-5F.

Design, Synthesis, and Pharmacological Screening of Pyridazinone Hybrids as Anticonvulsant Agents

A series of new hybrid benzimidazole containing pyridazinones derivatives were designed and synthesized in accordance with the pharmacophoric requirements essential for the anticonvulsant activity. The synthesized compounds were evaluated for anticonvulsant activity on mice by the gold standard maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ)-induced seizure models. Among the compounds tested, SS-4F showed significant anticonvulsant activity in both the screens with ED50 values of 25.10 and 85.33 mg/kg in the MES and scPTZ screens, respectively. Compound SS-4F emerged as safer and effective anticonvulsant due to its several-fold higher protective indices. Further, the gamma-aminobutyric acid (GABA) estimation result showed a marked increase in the GABA level (1.7-fold) as compared to the control, which was further confirmed by good binding properties with the GABAA receptor.

Nonsteroidal progesterone receptor ligands. 1. 3-Aryl-1-benzoyl-1,4,5,6- tetrahydropyridazines

-